

## County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 1<sup>st</sup> November 2018**

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **G-** Second line / alternative green drug
- G+** **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- A** **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
None				
<b>2) New Requests</b>				
<b>PLENVU®</b>  <b>Macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulphate anhydrous, electrolytes</b>				For bowel cleansing in adults (>18years of age) prior to any procedure requiring a clean bowel Bowel cleansing prior to Colonoscopy and also for CT Virtual Colonoscopy in those patients who cannot tolerate Moviprep.  <b>Decision:</b> Plenvu approved as an alternative to Moviprep in patients who cannot have Picolax. The intention is not to have this as an option in the current bowel preparations protocol nor is the intention to add this product to the current PGD for bowel preparatios. Plenvu will be reserved for prescribing by a consultant.
<b>3) New formulations &amp; extensions to use</b>				
None				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>5) Products considered by NICE</b>				
TA534: Dupilumab for treating moderate to severe atopic dermatitis	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA536: Alectinib for untreated ALKpositive advanced non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA538: Dinutuximab beta for treating neuroblastoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>7) Appeals against earlier decisions by the APC</b>				
None				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>8) Products considered by NTAG</b>				
<b>Ferric Maltol for the treatment of iron deficiency anaemia in Inflammatory Bowel Disease only (updated)</b>	✓ <b>G+</b>			<p>The formulary will reflect the NTAG position.</p> <p>Recommended as an option prior to IV iron and after trial of at least two oral ferrous salts.</p> <p>Approved change from RED to Green+ status.</p>
<b>Ferric Maltol for the treatment of iron deficiency anaemia in patients without Inflammatory Bowel Disease</b>	✓ <b>G+</b>			<p>The formulary will reflect the NTAG position.</p> <p>Recommended as an option prior to IV iron and after trial of at least two oral ferrous salts.</p>
<b>8) Miscellaneous decisions by the APC</b>				
<b>Opicapone 50mg capsules</b>	✓ <b>G+</b>			<p>For the treatment of Parkinson's disease – second or third line - used in patients who have tried and failed on entacapone.</p> <p><b>Decision:</b> Approved. First supply must be from specialist. Is on formulary in Tees and this is causing some cross boundary issues. (Also on NoT formulary)</p>
<b>Enoxaparin BECAT name change to AROVI</b>				<b>Decision:</b> Approve name change on formulary.
<b>Adrenaline autoinjectors – add Emerade®</b>	✓ <b>G</b>			<p><b>Decision:</b> Agreed to add to formulary due to current supply issues with EpiPen and Jext.</p> <p>Also agreed to add 500microgram strength as per NoT formulary for use in the emergency treatment of anaphylaxis for patients with a BMI of &gt;40 or who have required more than one auto-injector previously to control symptoms. Specialist immunologist initiation only.</p>

The following guidelines were presented to and approved at the November 2018 meeting of the APC:

- County Durham & Darlington Osteoporosis Guideline
- County Durham Homely Remedies Policy for Nursing Homes
- RMOC Free of Charge Medicines Scheme Policy

The following Green+ drug information leaflets were presented to and approved at the November 2018 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the November 2018 meeting of the APC:

- Nil